LOS ANGELES, Sept 19 (Reuters) - Amgen Inc's (AMGN.O: Quote, Profile, Research) closely watched experimental osteoporosis drug significantly increased bone density in post-menopausal women through 48 months of treatment in a small mid-stage study, the head of a research team that studied the drug said on Wednesday.
